Version history

{
  "session_id": "sess_SDA-2026-04-15-gap-pubmed-20260411-080155-ea072afc",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "minimax:MiniMax-M2.7",
  "action": "synthesize",
  "content": "\n\n```json\n{\n  \"ranked_hypotheses\": [\n    {\n      \"rank\": 1,\n      \"hypothesis_id\": \"H1\",\n      \"title\": \"Gal3 CRD-Mediated Cross-Linking of pTau Oligomers Nucleates Fibril Formation\",\n      \"composite_score\": 0.61,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.60,\n        \"evidence_strength\": 0.45,\n        \"novelty\": 0.70,\n        \"feasibility\": 0.65,\n        \"therapeutic_potential\": 0.60,\n        \"druggability\": 0.70,\n        \"safety_profile\": 0.55,\n        \"competitive_landscape\": 0.80,\n        \"data_availability\": 0.50,\n        \"reproducibility\": 0.55\n      },\n      \"theorist_confidence\": 0.72,\n      \"skeptic_confidence\": 0.45,\n      \"expert_confidence\": \"moderate\",\n      \"evidence_for\": [\n        {\"claim\": \"Galectin-3 forms antiparallel dimers via the N-terminal tail, enabling bivalent CRD interactions\", \"pmid\": \"24872436\"},\n        {\"claim\": \"Lectins have been shown to catalyze amyloid fibril formation through cross-linking mechanisms\", \"pmid\": \"28542644\"},\n        {\"claim\": \"Tau is modified by O-GlcNAcylation at multiple sites which creates β-galactoside-like structures\", \"pmid\": \"29238063\"},\n        {\"claim\": \"Galectin-3 binding to tau is enhanced by phosphorylation rather than glycan modifications\", \"pmid\": \"37988169\"},\n        {\"claim\": \"CRD is a known small-molecule binding pocket with existing chemical matter (TD139, belapectin)\", \"pmid\": \"unpublished\"},\n        {\"claim\": \"No direct competition in neurodegeneration; favorable first-in-class opportunity\", \"pmid\": \"N/A\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"O-GlcNAc is a single N-acetylglucosamine moiety—not a β-galactoside—Gal3 CRD affinity for O-GlcNAc not demonstrated\", \"pmid\": \"24872436\"},\n        {\"claim\": \"Phosphorylation determines binding affinity, not glycan modifications; argues against CRD-glycan mechanism\", \"pmid\": \"37988169\"},\n        {\"claim\": \"Galectin inhibitors (lactulose analogs) do not consistently reduce tau aggregation in models\", \"pmid\": \"unpublished\"},\n        {\"claim\": \"Tau lacks canonical Gal3 glycan ligands; predominantly natively unfolded with limited glycosylation in brain\", \"pmid\": \"unpublished\"},\n        {\"claim\": \"Bivalent dimer may not efficiently cross-link larger heterogeneous oligomers\", \"pmid\": \"24872436\"}\n      ],\n      \"expert_therapeutic_recommendation\": \"Proceed with validation; existing CRD inhibitor scaffolds provide starting point for CNS optimization\",\n      \"key_gaps\": [\"Gal3-pTau binding affinity (Kd) undetermined\", \"Glycan dependency not proven\", \"CRD necessity not tested via CRD-deletion mutant\", \"Cellular compartment of action (intra vs extracellular) unresolved\"],\n      \"priority_experiments\": [\"ITC with recombinant Gal3 CRD vs pTau with/without PNGase F\", \"CRD point mutants (R144H, H158N) for fibrillation enhancement\", \"Gal3 CRISPR knockout in iPSC-derived neurons\"]\n    },\n    {\n      \"rank\": 2,\n      \"hypothesis_id\": \"H7\",\n      \"title\": \"Gal3 CRD Competition with O-GlcNAcylation at T149 Drives Conformational Transition to Fibril-Competent State\",\n      \"composite_score\": 0.565,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.55,\n        \"evidence_strength\": 0.45,\n        \"novelty\": 0.75,\n        \"feasibility\": 0.60,\n        \"therapeutic_potential\": 0.65,\n        \"druggability\": 0.70,\n        \"safety_profile\": 0.40,\n        \"competitive_landscape\": 0.60,\n        \"data_availability\": 0.50,\n        \"reproducibility\": 0.45\n      },\n      \"theorist_confidence\": 0.68,\n      \"skeptic_confidence\": 0.50,\n      \"expert_confidence\": \"mechanistically plausible, testable\",\n      \"evidence_for\": [\n        {\"claim\": \"O-GlcNAcylation at T149 protects against tau aggregation\", \"pmid\": \"29238063\"},\n        {\"claim\": \"Reduced brain O-GlcNAc levels correlate with tau pathology in AD\", \"pmid\": \"26339040\"},\n        {\"claim\": \"OGA inhibitors (Thiamet-G, MK-8719, ASN-290) exist and could test this mechanism\", \"pmid\": \"multiple\"},\n        {\"claim\": \"Gal3 CRD binds preferentially to β-galactosides over α-GalNAc\", \"pmid\": \"24872436\"},\n        {\"claim\": \"O-GlcNAc and phosphorylation at overlapping sites create competitive modification states\", \"pmid\": \"29238063\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Mechanistically inconsistent with H1—CRD binding to glycans vs competing with OGT are mutually exclusive\", \"pmid\": \"N/A\"},\n        {\"claim\": \"Gal3 does not regulate OGT activity—Gal3 is a lectin, not an enzyme\", \"pmid\": \"N/A\"},\n        {\"claim\": \"O-GlcNAc at T149 in human brain is low-abundance and contested\", \"pmid\": \"unpublished\"},\n        {\"claim\": \"OGA inhibitors increase global O-GlcNAc levels affecting thousands of proteins\", \"pmid\": \"unpublished\"},\n        {\"claim\": \"Gal3 antagonizing O-GlcNAcylation indirectly without direct CRD competition is alternative explanation\", \"pmid\": \"N/A\"}\n      ],\n      \"expert_therapeutic_recommendation\": \"Testable with existing OGA inhibitors; verify whether Thiamet-G reduces Gal3-pTau binding\",\n      \"key_gaps\": [\"T149 O-GlcNAc site occupancy in human brain uncertain\", \"Direct OGT-tau interaction not demonstrated\", \"Gal3 CRD affinity for O-GlcNAc-modified peptides unmeasured\"],\n      \"priority_experiments\": [\"T149A mutation in neurons with/without Gal3 overexpression\", \"OGT interaction with tau by GST-pulldown or co-IP\", \"Gal3 CRD specificity for O-GlcNAc-modified peptides\"]\n    },\n    {\n      \"rank\": 3,\n      \"hypothesis_id\": \"H4\",\n      \"title\": \"N-Terminal Gal3 Tetramerization Enables Liquid-Liquid Phase Separation That Concentrates pTau\",\n      \"composite_score\": 0.56,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.65,\n        \"evidence_strength\": 0.55,\n        \"novelty\": 0.90,\n        \"feasibility\": 0.25,\n        \"therapeutic_potential\": 0.70,\n        \"druggability\": 0.20,\n        \"safety_profile\": 0.50,\n        \"competitive_landscape\": 0.90,\n        \"data_availability\": 0.45,\n        \"reproducibility\": 0.50\n      },\n      \"theorist_confidence\": 0.70,\n      \"skeptic_confidence\": 0.55,\n      \"expert_confidence\": \"mechanistically compelling, pharmacologically challenging\",\n      \"evidence_for\": [\n        {\"claim\": \"Galectin-3 undergoes N-terminal dependent self-association and LLPS\", \"pmid\": \"33839685\"},\n        {\"claim\": \"Tau undergoes LLPS under aggregation-prone conditions\", \"pmid\": \"32398719\"},\n        {\"claim\": \"LLPS has been shown to accelerate amyloid fibril formation for multiple proteins (FUS, TDP-43)\", \"pmid\": \"32589925\"},\n        {\"claim\": \"Highest revised confidence among hypotheses after skeptic evaluation\", \"pmid\": \"N/A\"},\n        {\"claim\": \"Gal3 found in granulovacuolar degeneration bodies and pathological inclusions\", \"pmid\": \"30341090\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Gal3 LLPS in neurons unproven—Drosophila and cell-free systems may not translate\", \"pmid\": \"33839685\"},\n        {\"claim\": \"Tau LLPS relationship to pathology uncertain—may be protective mechanism\", \"pmid\": \"32398719\"},\n        {\"claim\": \"CRD domains may be sterically hindered from engaging tau within condensates if multimerization drives LLPS\", \"pmid\": \"N/A\"},\n        {\"claim\": \"GVD bodies may be aggresome-like structures, not LLPS-derived\", \"pmid\": \"30341090\"},\n        {\"claim\": \"Many proteins can undergo LLPS under artificial conditions without physiological relevance\", \"pmid\": \"unpublished\"}\n      ],\n      \"expert_therapeutic_recommendation\": \"Prioritize at basic science level (structural biology, cryo-EM) before committing to drug development; N-terminal is 'undruggable' via small molecules\",\n      \"key_gaps\": [\"Gal3 LLPS in human neurons not demonstrated\", \"Whether tau droplets lead to fibrils or represent distinct pathway\", \"Therapeutic modality for N-terminal PPI targeting undefined\"],\n      \"priority_experiments\": [\"FRAP of Gal3-tau co-condensates (liquid-like recovery t½ < 5 sec)\", \"Gal3Δ1-112 truncation with LLPS defect in neurons\", \"Number/phase diagram for Gal3-tau concentration dependence\"]\n    },\n    {\n      \"rank\": 4,\n      \"hypothesis_id\": \"H5\",\n      \"title\": \"Gal3 Binding Masks PP2A Dephosphorylation Sites on pTau, Stabilizing Pathogenic Phospho-Epitopes\",\n      \"composite_score\": 0.475,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.35,\n        \"evidence_strength\": 0.35,\n        \"novelty\": 0.60,\n        \"feasibility\": 0.50,\n        \"therapeutic_potential\": 0.55,\n        \"druggability\": 0.65,\n        \"safety_profile\": 0.45,\n        \"competitive_landscape\": 0.50,\n        \"data_availability\": 0.40,\n        \"reproducibility\": 0.40\n      },\n      \"theorist_confidence\": 0.62,\n      \"skeptic_confidence\": 0.40,\n      \"expert_confidence\": \"indirect pathway, PP2A activators already in development\",\n      \"evidence_for\": [\n        {\"claim\": \"PP2A is the major phosphatase for tau at multiple phospho-sites including Ser396/404\", \"pmid\": \"24906155\"},\n        {\"claim\": \"Galectin-3 binding to cell surface receptors can block phosphatase access\", \"pmid\": \"26436952\"},\n        {\"claim\": \"Hyperphosphorylated tau is the substrate for Gal3-enhanced fibrillation\", \"pmid\": \"37988169\"},\n        {\"claim\": \"PP2A activators (DT-061, fingolimod, sodium selenate) already in development\", \"pmid\": \"multiple\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Steric blocking of PP2A (~65 kDa) by Gal3 (~30 kDa) is implausible without structural model\", \"pmid\": \"N/A\"},\n        {\"claim\": \"PP2A reduction in AD attributed to expression changes, PTMs, SET—not Gal3-mediated blocking\", \"pmid\": \"24906155\"},\n        {\"claim\": \"Gal3 knockdown does not increase PP2A activity toward tau phospho-epitopes\", \"pmid\": \"unpublished\"},\n        {\"claim\": \"Gal3-pTau binding may be transient/low-affinity—PP2A could dephosphorylate during binding dwell time\", \"pmid\": \"N/A\"},\n        {\"claim\": \"PP2A-tau structures show different binding regions than Gal3 proposed binding site\", \"pmid\": \"24906155\"}\n      ],\n      \"expert_therapeutic_recommendation\": \"Indirect pathway with existing competitors; combination therapy with Gal3-targeting could prevent upstream event if validated\",\n      \"key_gaps\": [\"Gal3-PP2A spatial relationship not mapped\", \"Gal3-pTau-PP2A ternary complex not demonstrated\", \"Dephosphorylation rates with/without Gal3 not measured\"],\n      \"priority_experiments\": [\"Phosphatase assay with purified PP2A vs pTau with/without Gal3\", \"FPOP or HDX-MS mapping of tau surface accessibility\", \"PP2A docking motif mutant (tau RVxF) with/without Gal3\"]\n    },\n    {\n      \"rank\": 5,\n      \"hypothesis_id\": \"H3\",\n      \"title\": \"Gal3-Tau Interaction Recruits Hsp90 Chaperone Complex to Stabilize Early Oligomers\",\n      \"composite_score\": 0.42,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.40,\n        \"evidence_strength\": 0.35,\n        \"novelty\": 0.65,\n        \"feasibility\": 0.30,\n        \"therapeutic_potential\": 0.35,\n        \"druggability\": 0.60,\n        \"safety_profile\": 0.40,\n        \"competitive_landscape\": 0.40,\n        \"data_availability\": 0.40,\n        \"reproducibility\": 0.35\n      },\n      \"theorist_confidence\": 0.58,\n      \"skeptic_confidence\": 0.40,\n      \"expert_confidence\": \"indirect target; confounded by existing Hsp90 inhibitor programs\",\n      \"evidence_for\": [\n        {\"claim\": \"Hsp90 stabilizes aggregation-prone proteins in neurodegenerative disease\", \"pmid\": \"27436466\"},\n        {\"claim\": \"Galectin-3 interacts with Hsp90 in cancer cells via its N-terminal domain\", \"pmid\": \"25612657\"},\n        {\"claim\": \"Tau oligomers are protected from degradation when complexed with chaperones\", \"pmid\": \"30258081\"},\n        {\"claim\": \"Hsp90 is tractable target with multiple inhibitors in development\", \"pmid\": \"multiple\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Gal3-Hsp90 interaction characterized in cancer cells, not neurons\", \"pmid\": \"25612657\"},\n        {\"claim\": \"Hsp90 inhibitors reduce tau levels overall, not stabilize oligomers—opposite prediction of hypothesis\", \"pmid\": \"27436466\"},\n        {\"claim\": \"PU-H71 AD trial (NCT03102255) failed/terminated—Hsp90 inhibition not viable for tau\", \"pmid\": \"NCT03102255\"},\n        {\"claim\": \"Tau is not canonical Hsp90 client (IDP); indirect binding via adapters more likely\", \"pmid\": \"27436466\"},\n        {\"claim\": \"Hypothesis 4 LLPS also uses N-terminal—direct competition for same domain not addressed\", \"pmid\": \"N/A\"}\n      ],\n      \"expert_therapeutic_recommendation\": \"Do not pursue—Hsp90 inhibitors failed in AD trial; contradicts therapeutic prediction\",\n      \"key_gaps\": [\"Gal3-Hsp90-tau ternary complex not demonstrated\", \"Hsp90-tau interaction may be indirect\", \"N-terminal domain competition with H4 not resolved\"],\n      \"priority_experiments\": [\"Co-IP from AD brain for endogenous ternary complexes\", \"Hsp90 inhibitor with Gal3 KO (synergistic vs independent effects)\", \"FRET between Hsp90 and tau oligomers with/without Gal3\"]\n    },\n    {\n      \"rank\": 6,\n      \"hypothesis_id\": \"H6\",\n      \"title\": \"Gal3 Acts as a Molecular Glue Recruiting c-Abl Tyrosine Kinase to Phosphorylate Tau at Y197\",\n      \"composite_score\": 0.41,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.35,\n        \"evidence_strength\": 0.30,\n        \"novelty\": 0.75,\n        \"feasibility\": 0.30,\n        \"therapeutic_potential\": 0.40,\n        \"druggability\": 0.55,\n        \"safety_profile\": 0.50,\n        \"competitive_landscape\": 0.30,\n        \"data_availability\": 0.35,\n        \"reproducibility\": 0.30\n      },\n      \"theorist_confidence\": 0.55,\n      \"skeptic_confidence\": 0.38,\n      \"expert_confidence\": \"poor fit—c-Abl inhibitors failed in AD\",\n      \"evidence_for\": [\n        {\"claim\": \"c-Abl phosphorylates tau at Y197 and this modification promotes aggregation\", \"pmid\": \"27448977\"},\n        {\"claim\": \"Galectin-3 contains PXXP motifs that bind SH3 domains\", \"pmid\": \"12124733\"},\n        {\"claim\": \"c-Abl inhibitors (imatinib) reduce tau pathology in mouse models\", \"pmid\": \"29073491\"},\n        {\"claim\": \"Novel molecular scaffold mechanism if validated\", \"pmid\": \"N/A\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Nilotinib failed in Parkinson's dementia trial (NCT02949219)—futility\", \"pmid\": \"NCT02949219\"},\n        {\"claim\": \"Imatinib AD trial (NCT02169284) completed—no publication of positive results\", \"pmid\": \"NCT02169284\"},\n        {\"claim\": \"Gal3 proline-rich motif SH3 binding not biochemically validated\", \"pmid\": \"12124733\"},\n        {\"claim\": \"c-Abl is primarily nuclear in neurons—limited access to cytosolic/microtubule-associated tau\", \"pmid\": \"unpublished\"},\n        {\"claim\": \"Positive feedback loop (pY197 → increased Gal3 binding) not experimentally supported\", \"pmid\": \"N/A\"},\n        {\"claim\": \"Imatinib has poor BBB penetration—effects may be peripheral/off-target\", \"pmid\": \"29073491\"}\n      ],\n      \"expert_therapeutic_recommendation\": \"Do not pursue—c-Abl inhibitors failed across neurodegenerative indications\",\n      \"key_gaps\": [\"Gal3-c-Abl complex formation not demonstrated\", \"SH3 domain binding by Gal3 PXXP motifs unvalidated\", \"pY197-tau abundance in human AD brain uncertain\"],\n      \"priority_experiments\": [\"Gal3 knockdown in imatinib studies (rescue would indicate Gal3-c-Abl axis)\", \"Endogenous co-IP of Gal3-c-Abl in neurons\", \"Gal3 binding affinity for tau with/without Y197 phosphorylation\"]\n    },\n    {\n      \"rank\": 7,\n      \"hypothesis_id\": \"H2\",\n      \"title\": \"Gal3 Binds Phospho-Tau via an Arginine-Gated Phospho-Specific Pocket Distinct from the CRD\",\n      \"composite_score\": 0.395,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.25,\n        \"evidence_strength\": 0.25,\n        \"novelty\": 0.85,\n        \"feasibility\": 0.20,\n        \"therapeutic_potential\": 0.35,\n        \"druggability\": 0.30,\n        \"safety_profile\": 0.50,\n        \"competitive_landscape\": 0.90,\n        \"data_availability\": 0.15,\n        \"reproducibility\": 0.20\n      },\n      \"theorist_confidence\": 0.65,\n      \"skeptic_confidence\": 0.35,\n      \"expert_confidence\": \"premature—no structural validation\",\n      \"evidence_for\": [\n        {\"claim\": \"Galectin-3 contains multiple arginine-rich patches on its surface that can bind phospho-ligands\", \"pmid\": \"33168825\"},\n        {\"claim\": \"pSer396/pSer404 are major phospho-epitopes in Alzheimer's tau pathology\", \"pmid\": \"28973123\"},\n        {\"claim\": \"PP2A activity is reduced in tauopathy, maintaining hyperphosphorylation\", \"pmid\": \"29891713\"},\n        {\"claim\": \"Novel non-CRD binding mechanism would be highly differentiated\", \"pmid\": \"N/A\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"PMID:33168825 discusses Gal3 CRD arginine residues interacting with sialic acid carboxylate—not phospho-serine\", \"pmid\": \"33168825\"},\n        {\"claim\": \"Gal3 CRD structure (PDB:1A3K) shows shallow cleft optimized for hydroxyl groups—tetrahedral phospho-geometry incompatible\", \"pmid\": \"24872436\"},\n        {\"claim\": \"Proposed residues R76, R80, K81, R186 not spatially clustered; largely buried or peripheral\", \"pmid\": \"unpublished structural analysis\"},\n        {\"claim\": \"No direct structural evidence for phospho-specific binding pocket despite extensive Gal3 characterization\", \"pmid\": \"24872436\"},\n        {\"claim\": \"Alanine scanning of proposed patch not performed in context of tau binding\", \"pmid\": \"N/A\"}\n      ],\n      \"expert_therapeutic_recommendation\": \"Cannot proceed with drug development without structural validation; if validated, would represent novel druggable interface\",\n      \"key_gaps\": [\"No structural evidence for proposed pocket\", \"CRD remains primary characterized binding site\", \"Residues not spatially clustered for coherent surface\"],\n      \"priority_experiments\": [\"Crystallography/NMR with pTau peptides (pSer396, pSer404, pSer262)\", \"Gal3ΔCRD mutant for residual tau binding\", \"Phospho-serine peptide competition assays\"]\n    }\n  ],\n  \"knowledge_edges\": [\n    {\n      \"source\": \"LGALS3\",\n      \"edge_type\": \"protein_protein_interaction\",\n      \"target\": \"MAPT\",\n      \"direction\": \"bidirectional\",\n      \"context\": \"Gal3 enhances tau fibrillation; phosphorylation state determines binding affinity\",\n      \"pmids\": [\"37988169\", \"28973123\"]\n    },\n    {\n      \"source\": \"LGALS3\",\n      \"edge_type\": \"enhances_aggregation\",\n      \"target\": \"MAPT\",\n      \"direction\": \"LGALS3 → MAPT\",\n      \"context\": \"Gal3 promotes tau pathology in AD brain and mouse models\",\n      \"pmids\": [\"30341090\", \"37988169\"]\n    },\n    {\n      \"source\": \"LGALS3\",\n      \"edge_type\": \"forms_oligomer\",\n      \"target\": \"LGALS3\",\n      \"direction\": \"intramolecular\",\n      \"context\": \"Antiparallel dimer via N-terminal (1-112); enables bivalent CRD interactions\",\n      \"pmids\": [\"24872436\"]\n    },\n    {\n      \"source\": \"LGALS3\",\n      \"edge_type\": \"undergoes_LLPS\",\n      \"target\": \"condensates\",\n      \"direction\": \"LGALS3 → liquid droplets\",\n      \"context\": \"N-terminal dependent self-association; LLPS demonstrated in Drosophila and cell-free\",\n      \"pmids\": [\"33839685\"]\n    },\n    {\n      \"source\": \"MAPT\",\n      \"edge_type\": \"undergoes_LLPS\",\n      \"target\": \"condensates\",\n      \"direction\": \"MAPT → liquid droplets\",\n      \"context\": \"Tau undergoes LLPS under aggregation-prone conditions; relationship to pathology debated\",\n      \"pmids\": [\"32398719\"]\n    },\n    {\n      \"source\": \"MAPT\",\n      \"edge_type\": \"phosphorylated_at\",\n      \"target\": \"pSer396, pSer404, pSer262\",\n      \"direction\": \"MAPT → phospho-epitopes\",\n      \"context\": \"Major phospho-epitopes in AD; binding affinity for Gal3 determined by phosphorylation state\",\n      \"pmids\": [\"28973123\"]\n    },\n    {\n      \"source\": \"MAPT\",\n      \"edge_type\": \"O-GlcNAcylated_at\",\n      \"target\": \"T149\",\n      \"direction\": \"MAPT → O-GlcNAc-T149\",\n      \"context\": \"Protective modification; competes with phosphorylation; low abundance in human brain contested\",\n      \"pmids\": [\"29238063\"]\n    },\n    {\n      \"source\": \"MAPT\",\n      \"edge_type\": \"dephosphorylated_by\",\n      \"target\": \"PPP2CA/PPP2R2A\",\n      \"direction\": \"PPP2CA → MAPT\",\n      \"context\": \"PP2A is major tau phosphatase; activity reduced in tauopathy via multiple mechanisms\",\n      \"pmids\": [\"24906155\"]\n    },\n    {\n      \"source\": \"MAPT\",\n      \"edge_type\": \"phosphorylated_at_Y197\",\n      \"target\": \"pY197\",\n      \"direction\": \"ABL1 → MAPT\",\n      \"context\": \"Promotes aggregation; c-Abl can phosphorylate in vitro; abundance in AD uncertain\",\n      \"pmids\": [\"27448977\"]\n    },\n    {\n      \"source\": \"OGA\",\n      \"edge_type\": \"removes_O-GlcNAc\",\n      \"target\": \"MAPT\",\n      \"direction\": \"OGA → MAPT\",\n      \"context\": \"OGA inhibitor Thiamet-G increases O-GlcNAc and reduces tau pathology\",\n      \"pmids\": [\"29238063\", \"26339040\"]\n    },\n    {\n      \"source\": \"HSPCA\",\n      \"edge_type\": \"interacts_with\",\n      \"target\": \"LGALS3\",\n      \"direction\": \"bidirectional\",\n      \"context\": \"Gal3-Hsp90 interaction demonstrated in cancer cells via N-terminal domain; neuronal relevance unestablished\",\n      \"pmids\": [\"25612657\"]\n    },\n    {\n      \"source\": \"HSPCA\",\n      \"edge_type\": \"client_interaction\",\n      \"target\": \"MAPT\",\n      \"direction\": \"disputed\",\n      \"context\": \"Hsp90 stabilizes aggregation-prone proteins; tau not canonical client; indirect binding via adapters\",\n      \"pmids\": [\"27436466\"]\n    },\n    {\n      \"source\": \"ABL1\",\n      \"edge_type\": \"phosphorylates\",\n      \"target\": \"MAPT\",\n      \"direction\": \"ABL1 → MAPT\",\n      \"context\": \"c-Abl phosphorylates tau at Y197 promoting aggregation; primarily nuclear in neurons\",\n      \"pmids\": [\"27448977\"]\n    },\n    {\n      \"source\": \"LGALS3\",\n      \"edge_type\": \"localizes_to\",\n      \"target\": \"GVD\",\n      \"direction\": \"LGALS3 → inclusion\",\n      \"context\": \"Gal3 found in granulovacuolar degeneration bodies and NFT—may be passive recruitment\",\n      \"pmids\": [\"30341090\"]\n    },\n    {\n      \"source\": \"LGALS3\",\n      \"edge_type\": \"expressed_in\",\n      \"target\": \"microglia\",\n      \"direction\": \"intracellular\",\n      \"context\": \"Gal3 expressed in microglia and infiltrating immune cells in AD brain; neuronal vs glial role unresolved\",\n      \"pmids\": [\"30341090",
  "tokens_used": "5502",
  "persona_id": "persona-synthesizer"
}